San Francisco‑based Mirendil has closed a $1 billion Series A round to develop AI agents that conduct scientific experiments autonomously, aiming to shorten research timelines.

San Francisco‑based Mirendil has secured a $1 billion Series A investment to build AI‑driven lab automation that can design, execute, and analyze experiments without human intervention.

Funding round details

The round was led by several sovereign wealth funds and venture capital firms, with participation from existing backers. Mirendil plans to allocate the capital toward expanding its engineering team, scaling cloud infrastructure, and forging partnerships with research institutions.

Technology focus

At the core of Mirendil’s platform are large language model agents that orchestrate robotic workstations, interpret assay results, and iteratively refine experimental protocols. The system integrates with existing laboratory hardware through a unified API, enabling seamless deployment across biotech labs.

Market implications

Analysts expect AI‑powered automation to compress drug discovery timelines by months, potentially reducing R&D costs for pharmaceutical companies. Mirendil’s approach also opens opportunities for academic labs to conduct high‑throughput studies that were previously cost‑prohibitive.

  • Accelerated hypothesis testing
  • Reduced reagent waste
  • Continuous 24/7 experiment cycles
  • Scalable data capture for AI model training

For readers interested in broader AI developments, see the AI category on uxc.news for related coverage.

TechStartups coverage of Mirendil Series A funding

Track coverage on Momentum · More in AI.